Reata制药

RETA NASDAQ
84.87
+3.28
+4.02%
盘后: 84.87 0 0.00% 16:52 06/17 EDT
开盘
81.54
昨收
81.59
最高
85.71
最低
81.54
成交量
20.79万
成交均量(3M)
21.89万
52周最高
104.53
52周最低
33.39
换手率
0.69%
市值
25.51亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Reata制药 RETA股票价格,Reata制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.
展开 >

最近浏览

名称
价格
涨跌幅